These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

602 related items for PubMed ID: 31075187

  • 1. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
    Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS, Evobrutinib Phase 2 Study Group.
    N Engl J Med; 2019 Jun 20; 380(25):2406-2417. PubMed ID: 31075187
    [Abstract] [Full Text] [Related]

  • 2. Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
    Arnold DL, Elliott C, Martin EC, Hyvert Y, Tomic D, Montalban X.
    Neurology; 2024 Mar 12; 102(5):e208058. PubMed ID: 38335474
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
    Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D, evolutionRMS investigators.
    Lancet Neurol; 2024 Nov 12; 23(11):1119-1132. PubMed ID: 39307151
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
    Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A, Tolebrutinib Phase 2b Study Group.
    Lancet Neurol; 2021 Sep 12; 20(9):729-738. PubMed ID: 34418400
    [Abstract] [Full Text] [Related]

  • 5. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
    Becker A, Martin EC, Mitchell DY, Grenningloh R, Bender AT, Laurent J, Mackenzie H, Johne A.
    Clin Transl Sci; 2020 Mar 12; 13(2):325-336. PubMed ID: 31654487
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
    Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, Seitzinger A, Guehring H, Shaw J, Tomic D, Hyvert Y, Harlow DE, Dyroff M, Wolinsky JS.
    Mult Scler; 2024 Apr 12; 30(4-5):558-570. PubMed ID: 38436271
    [Abstract] [Full Text] [Related]

  • 7. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
    Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT, DEFINE Study Investigators.
    N Engl J Med; 2012 Sep 20; 367(12):1098-107. PubMed ID: 22992073
    [Abstract] [Full Text] [Related]

  • 8. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
    [Abstract] [Full Text] [Related]

  • 9. Placebo-controlled trial of oral laquinimod for multiple sclerosis.
    Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M, ALLEGRO Study Group.
    N Engl J Med; 2012 Mar 15; 366(11):1000-9. PubMed ID: 22417253
    [Abstract] [Full Text] [Related]

  • 10. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
    Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, CONFIRM Study Investigators.
    N Engl J Med; 2012 Sep 20; 367(12):1087-97. PubMed ID: 22992072
    [Abstract] [Full Text] [Related]

  • 11. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ, Figgitt DP.
    CNS Drugs; 2004 Sep 20; 18(6):379-96. PubMed ID: 15089110
    [Abstract] [Full Text] [Related]

  • 12. Determination of a clinically effective evobrutinib dose: Exposure-response analyses of a phase II relapsing multiple sclerosis study.
    Papasouliotis O, Mitchell D, Girard P, Dangond F, Dyroff M.
    Clin Transl Sci; 2022 Dec 20; 15(12):2888-2898. PubMed ID: 36126241
    [Abstract] [Full Text] [Related]

  • 13. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
    Kita M, Fox RJ, Gold R, Giovannoni G, Phillips JT, Sarda SP, Kong J, Viglietta V, Sheikh SI, Okwuokenye M, Kappos L.
    Clin Ther; 2014 Dec 01; 36(12):1958-1971. PubMed ID: 25315404
    [Abstract] [Full Text] [Related]

  • 14. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 01; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 15. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
    Caldwell RD, Qiu H, Askew BC, Bender AT, Brugger N, Camps M, Dhanabal M, Dutt V, Eichhorn T, Gardberg AS, Goutopoulos A, Grenningloh R, Head J, Healey B, Hodous BL, Huck BR, Johnson TL, Jones C, Jones RC, Mochalkin I, Morandi F, Nguyen N, Meyring M, Potnick JR, Santos DC, Schmidt R, Sherer B, Shutes A, Urbahns K, Follis AV, Wegener AA, Zimmerli SC, Liu-Bujalski L.
    J Med Chem; 2019 Sep 12; 62(17):7643-7655. PubMed ID: 31368705
    [Abstract] [Full Text] [Related]

  • 16. Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis.
    Steinmaurer A, Wimmer I, Berger T, Rommer PS, Sellner J.
    Curr Pharm Des; 2022 Sep 12; 28(6):437-444. PubMed ID: 34218776
    [Abstract] [Full Text] [Related]

  • 17. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
    Kappos L, Hartung HP, Freedman MS, Boyko A, Radü EW, Mikol DD, Lamarine M, Hyvert Y, Freudensprung U, Plitz T, van Beek J, ATAMS Study Group.
    Lancet Neurol; 2014 Apr 12; 13(4):353-63. PubMed ID: 24613349
    [Abstract] [Full Text] [Related]

  • 18. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
    Fox RJ, Chan A, Zhang A, Xiao J, Levison D, Lewin JB, Edwards MR, Marantz JL.
    Curr Med Res Opin; 2017 Feb 12; 33(2):175-183. PubMed ID: 27733070
    [Abstract] [Full Text] [Related]

  • 19. Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.
    Kappos L, Giovannoni G, Gold R, Phillips JT, Arnold DL, Hotermans C, Zhang A, Viglietta V, Fox RJ, DEFINE and CONFIRM study investigators.
    Eur J Neurol; 2015 Apr 12; 22(4):664-71. PubMed ID: 25557371
    [Abstract] [Full Text] [Related]

  • 20. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L, TOWER Trial Group.
    Lancet Neurol; 2014 Mar 12; 13(3):247-56. PubMed ID: 24461574
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.